Circulating angiogenic factor levels correlate with extent of disease and risk of recurrence in patients with soft tissue sarcoma
Circulating angiogenic factor levels correlate with extent of disease and risk of recurrence in patients with soft tissue sarcoma
复制标题
DOI：
10.1093/annonc/mdh309
复制
发表时间：
2004-08-01
影响因子：
50.5
通讯作者：
Singer, S
中科院分区：
文献类型：
--
作者：
Yoon, SS;Segal, NH;Singer, S
背景资料：肿瘤血管生成或新血管形成受促血管生成因子如血管内皮生长因子（VEGF）和碱性成纤维细胞生长因子（bFGF）与抗血管生成因子如内皮抑制素之间的平衡调节。为了研究软组织肉瘤（STS）中的这种血管生成平衡，从76名STS患者和15名健康对照中收集血液样品，结果：41例（54%）为原发性肿瘤，20例（26%）为局部复发，15例（20%）为伴或不伴局部疾病的转移性肿瘤。所有三种血管生成因子的水平在STS患者中高度可变。VEGF和bFGF的平均水平分别是对照组的12倍和14倍（P <10 cm）。有转移的患者内皮抑素水平比无转移的患者低45%（P=0.047）。在54例接受原发病切除或局部复发的患者中，术前bFGF水平低与随后复发的风险较高相关（P = 0.044）。结论：STS分泌的血管生成因子水平变化很大，特异性因子的水平可能与疾病的程度相关，预测复发的风险，并可能指导抗血管生成药物的使用。
Background: Tumor angiogenesis, or new blood vessel formation, is regulated by a balance between pro-angiogenic factors such as vascular endothelial growth factor (VEGF) and basic fibroblast growth factor (bFGF), and anti-angiogenic factors such as endostatin.Patients and methods: To investigate this angiogenic balance in soft tissue sarcomas (STS), blood samples were collected from 76 STS patients and 15 healthy controls, and analyzed for VEGF, bFGF and endostatin using quantitative enzyme-linked immunosorbent assays (ELISA).Results: Forty-one patients (54%) had primary tumors, 20 (26%) had local recurrences and 15 (20%) had metastatic disease with or without local disease. Levels of all three angiogenic factors were highly variable in STS patients. Mean levels of VEGF and bFGF were 12 and 14 times higher, respectively, in patients compared with controls (P10 cm in size. Patients with metastases had endostatin levels 45% lower than patients without metastases (P=0.047). In 54 patients who underwent resection of primary disease or local recurrence, low pre-operative bFGF level was associated with a higher risk of subsequent recurrence (P = 0.044).Conclusions: STS secrete widely variable levels of angiogenic factors, and levels of specific factors may correlate with extent of disease, predict risk of recurrence and possibly guide the use of anti-angiogenic agents.